Orvinols with mixed kappa/Mu opioid receptor agonist activity

Journal of Medicinal Chemistry

Volumn 56, Issue 8, 2013, Pages 3207-3216

  Greedy, Benjamin M ^a   Bradbury, Faye ^b   Thomas, Mark P ^a   Grivas, Konstantinos ^c   Cami Kobeci, Gerta ^a   Archambeau, Ashley ^b   Bosse, Kelly ^b   Clark, Mary J ^b   Aceto, Mario ^d   Lewis, John W ^a   Traynor, John R ^b   Husbands, Stephen M ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1',5ALPHA,14ALPHA) 1' (4,5 EPOXY 7,8 DIHYDRO 3 HYDROXY 6 METHOXY 17 CYCLOPROPYLMETHYL 6,14 ETHANO MORPHINAN 7 YL) 3' PHENYL PROPAN 1 OL; (1',5ALPHA,14ALPHA) 1' (4,5 EPOXY 7,8 DIHYDRO 3 HYDROXY 6 METHOXY 17 CYCLOPROPYLMETHYL 6,14 ETHANO MORPHINAN 7 YL) 3' PHENYL PROPAN 1' OL; (2',5ALPHA,14ALPHA) 2' (4,5 EPOXY 7,8 DIHYDRO 3 HYDROXY 6 METHOXY 17 CYCLOPROPYLMETHYL 6,14 ETHANO MORPHINAN 7 YL) 3' CYCLOHEXYL PROPAN 2' OL; (2',5ALPHA,14ALPHA) 2' (4,5 EPOXY 7,8 DIHYDRO 3 HYDROXY 6 METHOXY 17 CYCLOPROPYLMETHYL 6,14 ETHANO MORPHINAN 7 YL) 5' METHYL HEXAN 2' OL; DRUGS USED IN THE TREATMENT OF ADDICTION; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; PARTIAL AGONIST; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHO CELL; COCAINE DEPENDENCE; CRYSTAL STRUCTURE; DIASTEREOISOMER; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; GLIOMA CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MODEL; NONHUMAN; STEREOCHEMISTRY; VAS DEFERENS;

ANALGESICS; COCAINE-RELATED DISORDERS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MODELS, MOLECULAR; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876823658     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301543e     Document Type: Article

References (31)

1. Newman, A. H. Novel Pharmacotherapies for cocaine abuse 1997-2000 Expert Opin. Ther. Pat. 2000, 10, 1095-1122
2. Negus, S. S.; Mello, N. K.; Portoghese, P. S.; Lin, C. E. Effects of κ-opioids on cocaine self-administration by rhesus monkeys J. Pharmacol. Exp. Ther. 1997, 282, 44-55
3. Mello, N. K.; Negus, S. S. Effects of κ opioid agonists on cocaine- and food-maintained responding by rhesus monkeys J. Pharmacol. Exp. Ther. 1998, 286, 812-824
4. Mello, N. K.; Negus, S. S. Interactions between kappa opioid agonists and cocaine-preclinical studies. New medications for drug abuse Ann. N.Y. Acad. Sci. 2000, 909, 104-132
5. Glick, S. D.; Maissoneuve, I. M.; Raucci, J.; Archer, S. κ-Opioid inhibition of morphine and cocaine self-administration in rats Brain Res. 1995, 681, 147-152
6. Bidlack, J. M.; Cohen, D. J.; McLaughlin, J. P.; Lou, R.; Ye, Y.; Wentland, M. P. 8-Carboxamidocyclazocine: A long-acting, novel benzomorphan J. Pharmacol. Exp. Ther. 2002, 302, 374-380
7. Tzaferis, J. A.; McGinty, J. F. Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum Mol. Brain Res. 2001, 93, 27-35
8. Heidbreder, C.; Shippenberg, T. S. U69,593 prevents cocaine sensitization by normalizing basal accumbens dopamine NeuroReport 1994, 5, 1797-1800
9. Crawford, C. A.; McDougall, S. A.; Bolanos, C. A.; Hall, S.; Berger, S. P. The effects of the κ agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviours and Fos immunoreactivity Psychopharmacology 1995, 120, 392-399
10. Shippenberg, T. S.; LeFevour, A.; Heidbreder, C. H. κ-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine J. Pharmacol. Exp. Ther. 1996, 276, 545-554
11. Walsh, S. L.; Strain, E. C.; Abreu, M. E.; Bigelow, G. E. Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans Psychopharmacology 2001, 157, 151-162
12. Negus, S. S.; Mello, N. K. Effects of kappa opioid agonists on cocaine self-administration under a progressive ratio schedule in rhesus monkeys Drug Alcohol Depend. 2001b, 63 (Suppl. 1) S113
13. Johnson, R. E.; Chutuape, M. A.; Strain, E. C.; Walsh, S. L.; Stitzer, M. L.; Bigelow, G. E. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence N. Engl. J. Med. 2000, 343, 1290-1297
14. Cowan, A.; Lewis, J. W. Buprenorphine: Combatting Drug Abuse with a Unique Opioid; Wiley-Liss: New York, 1995.
15. Boura, A. L. A.; Fitzgerald, A. E. The pharmacology of N-(cyclopropylmethyl)-19-isopentyl-nororvinol hydrochloride. A potent and long lasting central depressant Br. J. Pharmacol. 1966, 26, 307-321
16. Coop, A.; Berzetei-Gurske, I.; Burnside, J.; Toll, L.; Traynor, J. R.; Husbands, S. M.; Lewis, J. W. Structural Determinants of Opioid Activity in the Orvinols and Related Structures. Ethers of 7,8-Cyclopenta-analogs of Buprenorphine Helv. Chim. Acta 2000, 83, 687-693
17. Lewis, J. W.; Husbands, S. M. The orvinols and related opioids-high affinity ligands with diverse efficacy profiles Curr. Pharm. Des. 2004, 10, 717-732
18. Grundt, P.; Martinez-Bermejo, F.; Lewis, J. W.; Husbands, S. M. Formic acid catalysed rearrangement of thevinols and their vinylogous analogues. Effects of 5β-methyl substitution Helv. Chim. Acta 2003, 86, 2287-2298
19. Bentley, K. W.; Hardy, D. G. Novel analgesics and molecular rearrangements in the morphine-thebaine group. III. Alcohols of the 6,14-endoethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine J. Am. Chem. Soc. 1967, 89, 3281-3292
20. Bentley, K. W.; Bower, J. D.; Lewis, J. W. Novel analgesics and molecular rearrangements in morphine-thebaine group 0.16. Some derivatives of 6,14-endo-etheno-7,8-dihydromorphine J. Chem. Soc., C 1969, 18, 2569-2572
21. Lee, K. H.; Woods, J. H.; Traynor, J. R. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors Eur. J. Pharmacol. 1999, 378, 323-330
22. Berzetei-Gurske, I. P.; White, A.; Polgar, W.; DeCosta, B. R.; Pasternak, G. W.; Toll, L. The in vitro pharmacological characterization of naloxone benzoylhydrazone Eur. J. Pharmacol. 1995, 277, 257-263
23. Traynor, J. R.; Nahorski, S. R. Modulation by mu-opioid agonists of guanosine-5′-O-(3-[S-35]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells Mol. Pharmacol. 1995, 47, 848-854
24. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human κ-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
25. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist Nature 2012, 485, 321-327
26. Aceto, M. D.; Harris, L. S.; Bowman, E. R. Etorphines: Mu-opioid receptor-selective antinociception and low physical dependence capacity Eur. J. Pharmacol. 1997, 338, 215-223
27. Husbands, S. M.; Lewis, J. W. Structural determinants of efficacy for κ-opioid receptors in the orvinol series: 7,7-Spiro analogues of buprenorphine J. Med. Chem. 2000, 43, 139-141
28. Katz, J. L.; Woods, J. H.; Winger, G. D.; Jacobson, A. E. Compounds of novel structure having kappa agonist behavioral effects in rhesus monkeys Life Sci. 1982, 31, 2375-2378
29. Lewis, J. W. Structure-Activity Relationships of Opioids-A Current Perspective; Proceedings of the VIIIth International Symposium on Medicinal Chemistry I; Swedish Pharmaceutical Press: Stockholm, Sweden, 1985; p 123.
30. Lewis, J. W. Ring C-Bridged Derivatives of Thebaine and Oripavine; Advances in Biochemical Psychopharmacology; Harris, B.; Smith, M.; Raven Press: New York, 1974; Vol 8, pp p123-136.
31. Husbands, S. M.; Lewis, J. W. Opioid ligands having delayed long-term antagonist activity: Potential pharmacotherapies for opioid abuse Mini-Rev. Med. Chem. 2003, 3, 137-144